Cleared Traditional

K200017 - Eclipse DermaFlex Cannula

K200017 is an FDA 510(k) clearance for Eclipse DermaFlex Cannula, manufactured by Eclipse Medcorp, LLC. The device is a Class 2 General Hospital device with product code FMI cleared through the Traditional 510(k) pathway after a 307-day FDA review.

K200017 · Eclipse Medcorp, LLC · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2020
Decision
307d
Days
Class 2
Risk

K200017 is an FDA 510(k) clearance for the Eclipse DermaFlex Cannula. Classified as Needle, Hypodermic, Single Lumen (product code FMI), Class II - Special Controls.

Submitted by Eclipse Medcorp, LLC (The Colony, US). The FDA issued a Cleared decision on November 5, 2020 after a review of 307 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5570 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Eclipse Medcorp, LLC devices

FDA 510(k) Submission Details - K200017

510(k) Number K200017 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 03, 2020
Decision Date November 05, 2020
Days to Decision 307 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
178d slower than avg
Panel avg: 129d · This submission: 307d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

FMI Device Classification - Class 2, Special Controls

Product Code FMI Needle, Hypodermic, Single Lumen
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5570
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FMI Needle, Hypodermic, Single Lumen

All 271
Devices cleared under the same product code (FMI) and FDA review panel - the closest regulatory comparables to K200017.
Promisemed Covered Safety Pen Needle
K202681 · Promisemed Hangzhou Meditech Co., Ltd. · Dec 2020
NovoFine Plus 32G Tip x 4 mm
K202005 · Novo Nordisk, Inc. · Dec 2020
Promisemed Triple Safety Pen Needle
K202682 · Promisemed Hangzhou Meditech Co., Ltd. · Nov 2020
Droplet Pen Needle 30G & 33G
K202340 · Htl-Strefa S.A · Oct 2020
Injection Pen Needle
K192464 · Gangan Medical Technology Jiangsu Co., Ltd. · Aug 2020
TK Safety Needle
K191644 · Anhui Tiankang Medical Technology Co., Ltd. · Aug 2020